Maxalt (Rizatriptan Benzoate)

Rizatriptan works by selectively stimulating 5‑HT1B and 5‑HT1D receptors in the brain. This action causes constriction of dilated cranial blood vessels and blocks the release of pain‑triggering neuropeptides, interrupting the migraine pain pathway.

The exact dose of Maxalt is determined by the prescribing healthcare professional based on individual patient factors. Common practice involves a single tablet taken at the first sign of a migraine, with a possible second dose if needed after a specified interval.

Safety data for Rizatriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made in consultation with a qualified healthcare provider.

To order Maxalt, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both Maxalt (rizatriptan) and sumatriptan belong to the triptan class and are used for acute migraine relief. Rizatriptan generally has a faster onset of action, while sumatriptan offers a broader range of dosage forms. Choice depends on individual response, tolerability, and physician preference.

Maxalt tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light, and ensure the container is tightly closed when not in use.

Maxalt is taken orally as a tablet with a glass of water. It can be taken with or without food, although taking it with food may delay absorption slightly. Patients should follow the dosing instructions provided by their prescriber.

Serious risks include cardiovascular events such as coronary artery spasm, myocardial infarction, or stroke, especially in patients with underlying heart disease. Additionally, serotonin syndrome can occur when combined with other serotonergic drugs, and severe allergic reactions may also be possible.

Maxalt should be avoided in individuals with a history of coronary artery disease, uncontrolled hypertension, peripheral vascular disease, hemiplegic or basilar migraine, or those taking MAO inhibitors or other serotonergic medications. A thorough medical assessment is essential before initiating therapy.